Trastorno por consumo de alcohol (TCA): Un ensayo con exenatida, el primer agonista GLP-1 aprobado para diabetes, no mostr efectos sustanciales en la reduccin del consumo
For patients outside that profile, it is an impractical choice not a bad product, but the wrong product for their situation
One tablet daily or alternate-day dosing may improve tolerance, as recommended by NICE Clinical Knowledge Summaries
However, even though they are similar, they are actually approved for different uses and populations
Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study
Sometimes the simplest habits make the biggest difference